Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Actemra | Tocilizumab | Arthritis, juvenile idiopathic | List with clinical criteria and/or conditions | Complete | ||
Actemra | Tocilizumab | Arthritis, polyarticular juvenile idiopathic | List with criteria/condition | Complete | ||
Actemra | Tocilizumab | Arthritis, rheumatoid | List with criteria/condition | Complete | ||
Actemra | Tocilizumab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
Aclasta | Zoledronic acid | Osteoporosis | List with clinical criteria and/or conditions | Complete | ||
Aclasta | Zoledronic acid | Osteoporosis, postmenopausal women | Do not list | Complete | ||
Abstral | Fentanyl citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
Abraxane | Nab-paclitaxel | Metastatic Pancreatic Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Abilify Maintena | Aripiprazole | Schizophrenia | List with criteria/condition | Complete | ||
Abilify | Aripiprazole | Depression, Major Depressive Disorder | Do not list | Complete |